Realm Therapeutics PLC Director/PDMR Shareholding (4271Z)
15 December 2017 - 6:00PM
UK Regulatory
TIDMRLM
RNS Number : 4271Z
Realm Therapeutics PLC
15 December 2017
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
Grant of Options
15 December 2017 - Realm Therapeutics plc (AIM: RLM), a clinical
stage biopharmaceutical company focused on leveraging its
proprietary immunomodulatory technology, announces the grant of
2,080,000 share options to its directors and senior management to
subscribe for ordinary shares of 10p each in the capital of the
Company (the "Options"), as detailed below. All Options were
granted on 13 December 2017 (the "Grant Date"), have an exercise
price of 38.5 pence each and a ten-year term.
Grants to Executive Directors vest one-third per year on each of
the first three anniversaries of the Grant Date on the basis of
attainment of certain key performance measures relating to clinical
development and other strategic targets, which will be evaluated on
the relevant anniversaries. Grants to the Chief Medical Officer and
Non-Executive Directors vest one-third per year on each of the
first three anniversaries of the Grant Date.
Grants made to Executive Directors under the Realm Therapeutics
plc Executive Omnibus Incentive Plan 2016 (the "Plan") are noted
below.
Name Number of Options
Granted
Alex Martin (Chief Executive
Officer) 830,000
Marella Thorell (Chief Financial
& Operating Officer) 350,000
In addition, Christian Peters (Chief Medical Officer) has been
granted 350,000 options.
Grants made to Non-Executive Directors, under individual
agreements which are subject to the provisions of the Plan, are
noted below. Mr. Zweifach's grant relates to his initial
appointment to the Board.
Name Number of Options
Granted
Charles Spicer (Non-Executive
Chairman) 100,000
William Birkett (Senior Independent
Non-Executive Director) 100,000
Balkrishan (Simba) Gill (Non-Executive
Director) 100,000
Ivan Gergel (Non-Executive Director) 100,000
Sanford (Sandy) Zweifach (Non-Executive
Director) 150,000
Following the above grants there is a total of approximately
11.4 million options over ordinary shares outstanding which
represents approximately 9.8% of the current issued share capital
of the Company.
Contact:
Realm Therapeutics plc
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating
Officer
Outside US: +44 (0) 20 3727 1000
US: +1 212 600 1902
Argot Partners
Stephanie Marks
+1 212 600 1902
FTI Consulting
Simon Conway / Mo Noonan
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer
+44 (0) 20 7496 3000
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company
focused on developing novel immunomodulatory therapies to protect
and improve the lives of adults and children. The Company has
initiated drug development programs, based on its proprietary
hypochlorous acid technology at high concentrations. The Company
believes its formulations have novel immunomodulatory activity with
potential application for the treatment of diseases in a number of
therapeutic areas, including Dermatology and Ophthalmology.
Additional Disclosure
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
1 Details of the person discharging managerial
responsibilities/person closely associated
with them
---- -------------------------------------------------------------------
a) Name 1. Alex Martin
2. Marella Thorell
3. Christian Peters
4. Sanford (Sandy)
Zweifach
5. Charles Spicer
6. William Birkett
7. Balkrishan (Simba)
Gill
8. Ivan Gergel
---- --------------------------------- --------------------------------
2 Reason for notification
---- -------------------------------------------------------------------
a) Position/status 1. Chief Executive
Officer
2. Chief Financial
& Operating Officer
3. Chief Medical
Officer
4. Non-Executive
Director
5. Non-Executive
Chairman
6. Senior Independent
Non-Executive Director
7. Non-Executive
Director
8. Non-Executive
Director
---- --------------------------------- --------------------------------
b) Initial notification/Amendment Initial Notification
---- --------------------------------- --------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- -------------------------------------------------------------------
a) Name Realm Therapeutics
PLC
---- --------------------------------- --------------------------------
b) LEI n/a
---- --------------------------------- --------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- -------------------------------------------------------------------
a) Description of the financial Ordinary shares
instrument, type of instrument in Realm Therapeutics
Identification code PLC
ISIN: GB00B3XBCR18
---- --------------------------------- --------------------------------
b) Nature of transaction Grant of options
over 2,080,000 shares
under the Realm
Therapeutics plc
Executive Omnibus
Incentive Plan 2016
and individual agreements
---- --------------------------------- --------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- --------------------------------- ---------------- --------------
1. 38.50 830,000
pence
2. 38.50
pence 350,000
3. 38.50 350,000
pence
4. 38.50
pence 150,000
5. 38.50
pence 100,000
6. 38.50
pence 100,000
7. 38.50
pence 100,000
8. 38.50
pence 100,000
------------------------------------------------------- --------------
d) Aggregated information n/a
* Aggregated volume (Single transaction
for each recipient
of options)
* Price
---- --------------------------------- --------------------------------
e) Date of the transaction 13 December 2017
---- --------------------------------- --------------------------------
f) Place of the transaction Outside a trading
venue
---- --------------------------------- --------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFLDFILSLID
(END) Dow Jones Newswires
December 15, 2017 02:00 ET (07:00 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2024 to Jun 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Jun 2023 to Jun 2024